SIRPαFc treatment targets human acute myeloid leukemia stem cells

Oleksandr Galkin; Jessica McLeod; James A Kennedy; Liqing Jin; Nathan Mbong; Mark Wong; Robert A Uger; Mark D Minden; Jayne S Danska; Jean C Y Wang

doi:10.3324/haematol.2019.245167

SIRPαFc treatment targets human acute myeloid leukemia stem cells

Haematologica. 2021 Jan 1;106(1):279-283. doi: 10.3324/haematol.2019.245167.

Authors

Affiliations

¹ Princess Margaret Cancer Centre, University Health Network, Toronto, ON.
² Trillium Therapeutics Inc., Mississauga, ON.
³ Princess Margaret Cancer Centre, University Health Network, University of Toronto.
⁴ Hospital for Sick Children, University of Toronto, Toronto, ON.

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Humans
Immunoglobulin G
Leukemia, Myeloid, Acute* / drug therapy
Leukemia, Myeloid, Acute* / genetics
Neoplastic Stem Cells
Stem Cells

Substances

Immunoglobulin G
TTI-621

Grants and funding

Funding: this work was funded by the Government of Canada through Genome Canada and the Ontario Genomics Institute (OGI-091) with funds from the Government of Ontario and Trillium Therapeutics Inc.